Everolimus, sirolimus and imatinib were all classified as moderate inhibitors. Other anticancer agents showed weak inhibition.
Everolímus, sirolímus og imatinib voru flokkuð sem millisterkir hemlar en önnur krabbameinslyf sýndu litla hömlun.